Having established a U.S. beachhead with its $2.4 billion deal for Shire’s oncology business, Servier says it has found just the right person to oversee it: Shire executive David K. Lee. More: Servier picks Shire executive to run U.S. business
read moreLittle more than a week after Pfizer drew praise from President Donald Trump for simply delaying price increases on 40 drugs, Merck pledged “responsible pricing”—including some cuts—but a closer look at the company’s strategies reveals it really isn’t changing all
read moreShares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion. More: PureTech lifted by news of
read moreClinicians in the UK should have the option to prescribe cannabis-derived medicinal products where appropriate, drug experts have concluded, paving the way for laws prohibiting their use to be relaxed. More: UK drug advisors recommend rescheduling of medical cannabis Source:
read moreAllergan, Molecular Partners’ abicipar has shown non-inferiority to Novartis’ Lucentis but with fewer injections in late-stage trials involving patients with neovascular age-related macular degeneration. More: Allergan, Molecular Partners’ AMD drug non-inferior to Lucentis Source: News
read moreA price cut has secured NHS funding for Advanced Accelerator Applications’ Lutathera as a treatment for some neuroendocrine tumours (NETs). More: NICE backs radionuclide therapy for some neuroendocrine tumours Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals